Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276329 | 0.86 | NAMPT (0.68) | NAMPTSLC2A1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6282566 | 0.84 | NAMPT (0.57) | NAMPTSLC2A1ALDH1A1PAX8SMN1; SMN2 | |
| SCHEMBL18725052 | 0.80 | KEAP1 (0.71) | NAMPTPAX8SMN1; SMN2LMNAMAPT | |
| SCHEMBL534569 | 0.78 | LMNA (0.63) | NAMPTPAX8SMN1; SMN2LMNANR3C2 | |
| SCHEMBL28391735 | 0.77 | NAMPT (0.49) | NAMPTSLC2A1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL750261 | 0.76 | MEN1 (0.58) | NAMPTPAX8SMN1; SMN2LMNAMAPT | |
| SCHEMBL533757 | 0.76 | LMNA (0.56) | NAMPTALDH1A1PAX8SMN1; SMN2LMNA | |
| SCHEMBL15651151 | 0.76 | CA12 (0.59) | NAMPTALDH1A1PAX8SMN1; SMN2LMNA | |
| SCHEMBL12469095 | 0.76 | NAMPT (0.91) | NAMPTSLC2A1ALDH1A1 | |
| SCHEMBL28413113 | 0.76 | NAMPT (0.64) | NAMPTALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1625549-A | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER PROD INC (US) | 2005-06-08 | — | — | CN | claimed |
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1470109-A1 | METABOLITES OF (3- [(4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL -PHENOXY)-ACETIC ACID | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | claimed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | claimed |
| WO-2003064391-A1 | METABOLITES OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | claimed |
| CN-1625549-A | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER PROD INC (US) | 2005-06-08 | — | — | CN | disclosed |
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1470109-A1 | METABOLITES OF (3- [(4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL -PHENOXY)-ACETIC ACID | Pfizer Products Inc. (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | disclosed |
| WO-2003064391-A1 | METABOLITES OF (3-{[4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO]-METHYL}-PHENOXY)-ACETIC ACID | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | ABAT, BCAT2, PC | NAMPT 2536/4885SLC2A1 2029/4885ALDH1A1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.